VFA
IPXL

Virtus Fund Advisers’s Impax Laboratories, Inc. IPXL Stock Holding History

Virtus Fund Advisers’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-5,978
Closed -$179K – 2370
2014
Q2 		$179K Buy
+5,978
New +$161K ﹤0.01% 1014

Other funds holding IPXL

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Virtus Fund Advisers's IPXL Position: Q3 2014 in Review

Virtus Fund Advisers sold out of Impax Laboratories, Inc. (IPXL) in Q3 2014, closing a stake of 5,978 shares — an estimated $179K sold.

Virtus Fund Advisers first reported a position in IPXL in Q2 2014 and held it in 1 quarter. The position peaked at $179K in Q2 2014. 162 funds tracked by Wall St. Rank hold IPXL as of Q3 2014.

  • Virtus Fund Advisers reported no remaining Impax Laboratories, Inc. position as of Q3 2014 after selling out during the quarter.
  • Virtus Fund Advisers sold 5,978 Impax Laboratories, Inc. shares in Q3 2014, an estimated $179K.
  • Virtus Fund Advisers first reported a position in Impax Laboratories, Inc. in Q2 2014 and held it in 1 quarter.
  • Virtus Fund Advisers's Impax Laboratories, Inc. position peaked at $179K in Q2 2014.
  • 162 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q3 2014.

Based on Virtus Fund Advisers's 13F filing for Q3 2014, filed 31 Oct 2014.